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Pharmacological ascorbate is currently used as an anti-cancer treatment, potentially in
combination with radiation therapy, by integrative medicine practitioners. In the acidic,
metal-rich tumor environment, ascorbate acts as a pro-oxidant, with a mode of action
similar to that of ionizing radiation; both treatments kill cells predominantly by free radical-
mediated DNA damage.The brain tumor, glioblastoma multiforme (GBM), is very resistant
to radiation; radiosensitizing GBM cells will improve survival of GBM patients. Here, we
demonstrate that a single fraction (6 Gy) of radiation combined with a 1 h exposure to
ascorbate (5 mM) sensitized murine glioma GL261 cells to radiation in survival and colony-
forming assays in vitro. In addition, we report the effect of a single fraction (4.5 Gy) of
whole brain radiation combined with daily intraperitoneal injections of ascorbate (1 mg/kg)
in an intracranial GL261 glioma mouse model. Tumor-bearing C57BL/6 mice were divided
into four groups: one group received a single dose of 4.5 Gy to the brain 8 days after
tumor implantation, a second group received daily intraperitoneal injections of ascorbate
(day 8–45) after implantation, a third group received both treatments and a fourth control
group received no treatment. While radiation delayed tumor progression, intraperitoneal
ascorbate alone had no effect on tumor progression. Tumor progression was faster in
tumor-bearing mice treated with radiation and daily ascorbate than in those treated with
radiation alone. Histological analysis showed less necrosis in tumors treated with both
radiation and ascorbate, consistent with a radio-protective effect of ascorbate in vivo. Dis-
crepancies between our in vitro and in vivo results may be explained by differences in the
tumor microenvironment, which determines whether ascorbate remains outside the cell,
acting as a pro-oxidant, or whether it enters the cells and acts as an anti-oxidant.
Keywords: pharmacological ascorbate, radiation, intracranial mouse glioma model, GL261, radioprotection,
radiosensitization
INTRODUCTION
The use of high (pharmacological) doses of ascorbate for the treat-
ment of cancer is highly controversial [reviewed by Ref. (1)].
Although most mammals make their own ascorbate from glu-
cose in the liver, humans and other primates (as well as guinea
pigs and bats) obtain ascorbate from their diet as they lack a func-
tional gulonolactone oxidase necessary for the last step of ascorbate
synthesis (2). Regardless of source, systemic ascorbate levels are
very tightly regulated by controlled uptake into (1) the blood
stream through the intestinal epithelium (via high affinity sodium-
dependent vitamin C transporters, SVCT1) and (2) into body
tissues (via SVCT2), followed by (3) renal clearance (via SVCT1)
to plateau at 40–60µM (3). Intravenous/intraperitoneal injec-
tion of high-dose ascorbate (0.5–1.25 g/kg in humans; 1–4 g/kg in
mice) can bypass regulation to generate serum levels of 30 mM for
about 2 h (4, 5). Such high concentrations of ascorbate have been
reported to generate extracellular hydrogen peroxide, particularly
in the acidic metal-rich environment of solid tumors [reviewed
by Ref. (1)]. Hydrogen peroxide diffuses into cells where it gener-
ates reactive oxygen species (ROS), such as hydroxyl radicals (6),
which overwhelm the anti-oxidant defense system, resulting in
DNA damage (7, 8). The extracellular addition of catalase abro-
gates the pro-oxidant effect of high-dose ascorbate (6–9), verifying
the role of extracellular hydrogen peroxide in its mechanism of
action.
High-dose ascorbate is well tolerated in cancer patients who
have normal renal function, do not have glucose-6-phosphate
dehydrogenase deficiency or iron overload (4, 5) and has been
shown to delay tumor growth in rodent xenograft models (10).
However, high-dose ascorbate as a single agent has never been
reported to cure cancer in animals or humans. Recent preclinical
research has therefore focused on combining high-dose ascorbate
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with chemotoxic anticancer drugs such as Carboplatin and Pacli-
taxel for ovarian cancer (11), Gemcitabine for pancreatic cancer
(12), Epigallocatechin-3-gallate plus Gemcitabine for malignant
mesothelioma (13), Vincristine (14), and glycolytic inhibitors for
small cell lung cancer (15). Potentiation of the hydrogen per-
oxide generating effect of ascorbate in vitro has been reported
for inhibitors of hydrogen peroxide metabolism in pancreatic
cancer (16), alpha-tocopherol succinate in prostate cancer (17),
manganoporphyrins in breast cancer (18) and pancreatic cancer
(19), and phenylaminonaphthoquinones in bladder cancer (20).
Increased sensitivity to Docetaxel, Epirubicin, Irinotecan, and 5-
FU after ascorbate exposure has been attributed to G0/G1 arrest
in prostate carcinoma cells (21).
Only three small clinical trials have so far been published that
have evaluated the effect of high-dose ascorbate combination ther-
apy in metastatic ovarian cancer [with carboplatin plus paclitaxel;
n= 25 (11)] and metastatic pancreatic cancer [with gemcitabine;
n= 9 (22) and with gemcitabine plus erlotinib; n= 14 (23)]. All
three trials noted that patients on the ascorbate plus chemother-
apy arm lived longer than those taking conventional chemotherapy
alone. However, the increase in survival time was not statistically
significant due to the small patient numbers typical of stage I tri-
als (11, 22, 23). With respect to side-effects, all trials demonstrated
a lack of ascorbate-related toxicities. In fact, two trials (11, 22)
reported fewer grade 1 and 2 chemotherapy-related toxicities with
the addition of ascorbate to standard chemotherapy.
Radiation resistance of the primary adult brain cancer, glioblas-
toma multiforme (GBM), is a key factor in poor patient outcomes
(24). As the blood–brain barrier limits chemotherapy options for
brain tumors radiation is a primary treatment. Patient outcomes
can be improved by either escalation of radiation dose to the tumor
(25) or by increasing the sensitivity of GBMs to radiation. Because
ionizing radiation kills cells mainly by generating free radicals that
cause double stranded DNA breaks (DSB) (26), one approach to
radio-sensitization would be to combine radiation therapy with
compounds that also generate free radicals. As many cancers have
inferior radical scavenging and DNA repair capability (27), a com-
bination of treatments that increase free radical production should
theoretically affect cancer cells more than normal cells.
Two in vitro studies have shown that high-dose ascorbate
radiosensitized primary GBM cells isolated from tumors of GBM
patients by generating extracellular hydrogen peroxide and induc-
ing S/G2 arrest, interfering with DNA repair (7, 8). Interestingly,
both ionizing radiation and high-dose ascorbate were shown to
increase labile iron levels in pancreatic tumor homogenates from
athymic nude mice (28). Catalytic metals can accelerate ascorbate
oxidation, leading to increased generation of hydrogen perox-
ide (29). Radio-sensitization of highly aggressive radio-resistant
GBMs has significant clinical implications. The addition of ascor-
bate to radiation protocols would allow for superior tumor control
at lower radiation doses, resulting in less severe acute and chronic
brain toxicities. The first report of ascorbate chemoradiation in
mice was published in 1996 when Taper and colleagues showed
that pretreating intramuscularly transplanted liver tumors with
ascorbate and menadione (Vitamin K3) potentiated the effect
of a single dose of 20–50 Gy of X-ray irradiation (30). Here,
we investigate the effects of high-dose ascorbate and radiation
on tumor progression and tumor histology in an intracranial
mouse glioma model, where GL261 mouse glioma cells are
injected directly into the brain of immunocompetent C57BL/6
mice.
MATERIALS AND METHODS
MATERIALS
Unless otherwise noted, tissue plasticware was purchased from
Nunc (ThermoFisher Scientific, Auckland, New Zealand); all cell
culture reagents were from Gibco BRL (Invitrogen, Auckland, New
Zealand). Sodium ascorbate and all other chemicals and reagents
were from Sigma Chemical Company (St. Louis, MO, USA).
CELL LINES
The mouse glioma cell line, GL261 was obtained from the NCI
tumor cell line repository (Fredrick, MD). GL261 cells were grown
in RPMI-1640 supplemented with 20% (v/v) FBS, GlutaMAX-
1 (2 mM), 25µg/mL penicillin, 25µg/mL streptomycin and
maintained in a humidified incubator at 37°C/5% CO2.
IRRADIATION OF GL261 CELLS
GL261 cells were seeded 24 h prior to treatment in six well plates (3
to 5× 104/well). Cells were 30–40% confluent and growing expo-
nentially on the day of treatment. Cells were irradiated with 1, 3,
6, or 9 Gy using Cesium-137 γ-rays (Gammacell 3000 Elan, Best
Theratronics) for viability assays and with 6 Gy for clonogenic-
ity assays. After irradiation, the cells were re-incubated in fresh
medium.
ASCORBATE TREATMENT OF GL261 CELLS
Exponentially growing 30–40% confluent GL261 cells were seeded
24 h prior to treatment in six well plates (3 to 5× 104/well).
Cells were exposed to 5 mM ascorbate in media for 1 h, washed
in Dulbecco’s Phosphate Buffer Saline (PBS, 1.4 M NaCl, 27 mM
KCl, 170 mM NaH2PO4, 17.6 mM KH2PO4) and re-incubated in
fresh medium. Cells that received radiation were irradiated in the
presence of ascorbate.
VIABILITY OF GL261 CELLS
GL261 cells were collected 48 h after radiation (1, 3, 6, and 9 Gy)
by trypsinization, washed in PBS, and resuspended in 1µg/mL
propidium iodide, for cell count and dye exclusion using flow
cytometry using a BD FACSort (Becton Dickinson, San Jose, CA,
USA). All viability assays were completed at least three times in
triplicate.
CLONOGENICITY OF GL261 CELLS
Colony-forming ability was determined as described by Franken
et al. (31). GL261 cells at 30–40% confluency in 100 mm dishes
were treated with 6 Gy, 5 mM ascorbate or both 6 Gy and 5 mM
ascorbate, trypsinized, counted, and re-plated at varying dilutions,
and incubated for 12–14 days. Plates were fixed and stained in 0.5%
(w/v) methylene blue solution in 50% (v/v) methanol for 1 h, and
colonies consisting of at least 50 cells were counted. The surviv-
ing fraction of cells was calculated against the plating efficiency
of GL261 cells for each experiment. All clonogenic assays were
completed at least three times in triplicate.
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ANNEXIN V/PROPIDIUM IODIDE STAINING
Annexin V/propidium iodide staining was used to distinguish
between viable cells (A−/PI−), early apoptotic cells (A+/PI−) and
dead cells (A+/PI+). Cells were centrifuged at 130× g at room
temperature for 5 min, washed in phosphate buffered saline solu-
tion, pH 7.3 (PBS), and resuspended in Annexin V binding buffer.
Small aliquots (1× 106 cells) were transferred to 1.5 mL tubes and
spun at 2000 rpm for 2 min in a Biofuge fresco (Kendro,Auckland).
Most supernatant was removed and 5µL PI and 5µL FITC-labeled
AV was added to the wet pellets, which were vortexed. After 30 min
in the dark on ice, 500µL of Annexin V binding buffer was added;
the cells were centrifuged for 2 min at 2000 rpm, washed once
with Annexin V binding buffer, and resuspended in 1 mL of bind-
ing buffer in FACS tubes. Staining was analyzed by flow cytometry
using a BD FACSort (Becton Dickinson, San Jose, CA, USA). AV/PI
staining was completed three times.
DOUBLE STRANDED DNA BREAK ANALYSIS
Double stranded DNA breaks were determined at 2 and 24 h after
treatments by the extent of phosphorylation of the histone vari-
ant protein, H2AX, using FITC-labeled anti-γH2AX antibodies
in permeabilized cells (32). Cells were washed in PBS buffer and
distributed in 96 well plates (5× 105 cells/well), washed in 200µL
FACS buffer (PBS+ 1% BSA), pelleted at 2000 rpm (in a Megafuge
2.0R, Heraeus Germany centrifuge) for 2 min, and fixed in 200µL
BD Cytofix/Cytoperm solution. After 15 min incubation at 4°C,
cells were washed twice in 200µL 1× BD Perm/Wash buffer, incu-
bated at 4°C for 15 min, pelleted and resuspended in antibody
solution (50µL anti-γH2AX antibody or isotype control diluted
1: 500 in 1× BD Perm/Wash) at 4°C for 1 h, washed twice in 1×
BD Perm/Wash, and resuspended in 400µL FACS buffer. Stained
and unstained control cells were analyzed by flow cytometry.
INTRACRANIAL MOUSE MODEL
All experiments using mice were conducted in accordance with
the New Zealand Animal Welfare Act 19991 and were approved
by the Victoria University Animal Ethics Committee. Mouse
glioma GL261 cells were cultured to sub-confluence, washed in
PBS, and live cells implanted into the brain of 8- to 12-week
old (approx. 30 g) male C57BL/6 mice, following the procedure
described by Hunn et al. (33). Briefly, animals were anesthetized
by intraperitoneal (i.p.) injection of xylazine (100 mg/kg) and ket-
amine (10 mg/kg) (Phoenix Pharm), and Lacri-Lube (Allergan)
applied across the cornea of the eye. A burr hole was drilled in
the skull 0.1 mm posterior to the bregma and 2.3 mm lateral to
the midline. Live cells (5× 103 in 2µL of PBS) were adminis-
tered stereotactically (Stoelting Apparatus), into the burr hole,
using a Hamilton syringe with a 32-gauge needle. The needle was
advanced to a depth of 2.3 mm from the brain surface and the cell
suspension delivered slowly over the course of 2–3 min. Following
injection, the needle was left in place for 2 min, after which time,
it was raised to a depth of 1.5 mm below the brain surface and left
in place for an additional 1 min. Upon withdrawal of the needle,
the burr hole was sealed with bone wax and the incision sutured.
1www.legislation.govt.nz/act/public/1999/0142/latest/DLM49664.html
Animals received sub-cutaneous analgesics [Carprofen (5 mg/kg),
Norbrook Laboratories, and Buprenorphine (0.1 mg/kg), Renckitt
Benckiser Pharmaceuticals], to control post-operative pain. Ani-
mals were randomly assigned into control and treatment groups
(n= 5/group). Animals were weighed daily and humanely sacri-
ficed by cervical dislocation when weight loss occurred (>10% of
body weight) or until neurological signs of disease were evident,
whichever came first.
WHOLE BRAIN IRRADIATION OF MICE
Mice received a single dose of 4.5 Gy to the brain (and ≤1 Gy
to the shielded body) on day 8 after surgery, based on previous
work by Newcomb et al. (34). The Gammacell 3000 Elan irra-
diator irradiates the content of a steel cylinder with γ-rays from
a sealed Cesium-137 line source (length 27 cm, diameter 1.7 cm;
nominal activity 48 TBq). Tumor-bearing mice were anesthetized
and placed in an upright position, stabilized by tissue paper, in a
50 mL Falcon tube without a tip to facilitate breathing. The tube
was placed inside 2 cm thick custom-built lead shielding, which
exposes the head to radiation while shielding the body from the
ears down. The shielding was placed in the center of the steel
cylinder (Figure 1).
The radiation dose received by the head and the rest of
the body was verified using the thermoluminescence dosime-
try system located at the Blood and Cancer Center, Welling-
ton Hospital. The system utilizes thermoluminescent dosimeters
(TLDs) based on lithium fluoride crystals doped with magne-
sium and titanium (“TLD-100”), in chip form with dimensions of
3.2 mm× 3.2 mm× 0.9 mm (35, 36). Prior to use, the dosime-
ters were reset by annealing at high temperatures in an oven
(PTW-Freiburg TLDO) and sealed into plastic envelopes as rows of
separate dosimeters. In order to ensure the same radiation absorp-
tion and scatter properties as during the treatment of live mice,
the dosimeters were positioned between a culled mouse and a
FIGURE 1 | Irradiation setup for whole brain irradiation of mice. The
mouse is positioned in a Falcon tube (A), inside a 2 cm thick lead shielding
device (B) inside plastic rings (C) which are placed inside the aluminum
cylinder in the irradiator (D). Diagram of the irradiation setup (E).
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Falcon tube, along its axial length from the pelvis to the brain
region. The Falcon tube including mouse and dosimeters was
placed inside the lead shielding, and exposed for a set time in
the gamma irradiator. The time required to deliver approximately
4.5 Gy to the mouse head using our shielding – which blocks a frac-
tion of the radiation emitted by the source – was approximately
1.5 min. After irradiation, the TLDs underwent a pre-read anneal
cycle, followed by the readout in an automatic TLD reader (Har-
shaw QS 5500). The calibration of the dosimeters was performed
by exposing TLDs to a known radiation dose delivered by a 6 MV
X-ray beam from a linear accelerator at Wellington Hospital. This
dose was independently measured with a cylindrical ionization
chamber following local procedures based on absorbed dose to
water and calibration factors traceable to the Australian primary
standard for absorbed dose.
The measurements were subject to corrections for measured
variations in sensitivity for individual TLD chips, and the differ-
ence in beam energies for calibration (6 MV X-ray beam with mean
energy near 2 MeV) and measurements (662 keV gamma rays for
Cesium-137) (35–38). The reproducibility of the results was ver-
ified by repeating the TLD measurements for a small selection of
positions in the head region and body region, finding variations
not exceeding ±4%. Analysis of the results, including an estimate
of the uncertainties, indicates an absorbed dose of 4.5± 0.3 Gy
delivered to the brain region and a mean of 0.6± 0.04 Gy along
the mouse body within the shielding. Based on these results, an
acute whole body dose of 1 Sv is estimated, which is considered to
be non-lethal.
TREATMENT OF MICE WITH HIGH-DOSE ASCORBATE
Tumor-bearing mice received an i.p. injection of high-dose ascor-
bate, 2 h prior to irradiation and after that once daily (Mon–Fri)
from day 8 to 45 after surgery, at a concentration of 1 or 2 g/kg
bodyweight of a sterile neutralized ascorbate solution (Sigma)
in 1 mL of PBS buffer, similar to the procedure used by Chen
et al. (10).
HISTOLOGICAL ANALYSIS OF MOUSE BRAINS
The auto-fluorescent property of H&E stained blood was used to
quantify the amount of intravascular and extravascular blood in
each section. An Olympus 1× 51 inverted microscope and Olym-
pus DP72 camera were used to take fluorescent images of the
entire tumor at 4× using a mercury bulb and a band-pass filter to
measure wavelengths between 604 and 644 nm. ImageJ 1.48v2 was
used to measure the percentage of blood in the tumor. Fluorescent
images were converted into 8-bit grayscale images. The total area
of the tumor was measured by tracing around the tumor border
with the freehand selection tool. The threshold tool was adjusted
to select and measure only the auto-fluorescent blood in the image.
The following formula was used to convert these measurements
into the percentage of blood in the tumor:
percentage of tumor consisting of blood = area of blood
area of tumor
× 100
2http://imagej.nih.gov/ij/index.html
Necrosis was measured using brightfield images of the same H&E
stained sections. Areas of necrosis were traced around and mea-
sured with the freehand selection tool. The following formula was
used to convert these measurements into the percentage of necrosis
in the tumor:
percentage of tumor consisting of necrosis
= area of necrosis
area of tumor
× 100
STATISTICAL ANALYSIS
Statistical significance of differences in 48 h survival and clono-
genicity of GL261 cells between different treatments were cal-
culated using unpaired two-tailed student t tests (Microsoft v
2010; Redmond Campus, Redmond, Washington, DC, USA). The
Mantel–Cox log-rank test (Prism 5.0 Graph Pad Software, Inc.,
La Jolla, CA, USA) was performed to determine the statistical sig-
nificance between Kaplan–Meier survival curves. In all instances,
p< 0.05 was considered statistically significant.
RESULTS
SENSITIVITY OF GL261 CELLS TO RADIATION, ASCORBATE, AND
COMBINED TREATMENTS
GL261 is a mouse glioma cell line, which forms tumors in
immunocompetent C57BL/6 mice. We first tested the sensitivity
of GL261 cells in vitro to a single exposure of different doses of
radiation (Gy) (Figure 2A) and a 1 h exposure to different concen-
trations of ascorbate (AA) (Figure 2B). We have previously shown
that our GBM cell lines do not produce many DSB after a single
exposure of 1 or 3 Gy. All our in vitro research therefore has used
a single dose of 6 Gy to determine the effect of a radiation alone
and in combination with 5 mM ascorbate on viability, clonogenic-
ity, generation, and repair of DSBs and cell cycle progression (7,
8). Concentrations of 5 mM ascorbate have been used by a num-
ber of authors in the field [reviewed in Ref. (1)]. Similar to our
previous research with a panel of GBM cell lines (7, 8), GL261
cells sustained a substantial amount of DNA damage, as shown
by the percentage of cells with DSBs 2 h after treatments. Ini-
tial DNA damage as well as DNA damage repair was significantly
worse after combined treatment compared with single treatments
(Figure 2C). We determined the percentage of GL261 cell survival
after 48 h (Figure 2D) and colony-forming ability after 10–12 days
(Figure 2E), in response to both single and combined treatments.
Combining both treatments decreased 48 h survival and clono-
genicity compared with radiation treatment alone. GBM cells are
very resistant to apoptosis (7, 39). GL261 cells also did not undergo
apoptosis when exposed to single and combined treatments in vitro
(Figure 2F).
EFFECT OF RADIATION, ASCORBATE, AND COMBINED TREATMENTS ON
MOUSE SURVIVAL
Our next step was to validate the in vitro radio-sensitizing effect
of high-dose ascorbate on GL261 clonogenicity in an intracra-
nial mouse glioma model. Live GL261 cells (5× 103 in 2µL
of PBS) were implanted into the brain of 8- to 12-week-old
(approximately 30 g) male C57BL/6 mice. Tumor-bearing mice
were divided into four groups: one group received a single dose
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FIGURE 2 | Sensitivity of GL261 to radiation and ascorbate
treatments. (A) Cell survival 48 h after a 1 h exposure to different doses
of ascorbate (AA), measured by PI exclusion and flow cytometry; (B) cell
survival 5 days after irradiation with 1, 3, 6, and 9 Gy, measured by PI
exclusion and flow cytometry; (C) DNA damage and repair as fold
change (compared to control) of % cells with DSBs was measured as
the extent of H2AX phosphorylation (fluorescence intensity) using flow
cytometry and anti-γH2AX antibodies at 2 and 24 h after treatments;
(D) Cell survival 48 h after 6 Gy, 5 mM AA, or combined treatment as
measured by PI exclusion and flow cytometry; (E) clonogenicity
(colony-forming units) 10–12 days after 6 Gy, 5 mM AA, or combined
treatment. Colonies of 50 cells or more were visualized by methylene
blue staining, counted, and numbers are presented as percentage of
untreated controls. (F) Lack of apoptosis of GL261 cells 48 h after 6 Gy,
5 mM AA, or combined treatment as measured by FACs analysis of AV/PI
staining. Values are averages±SEM of at least three different
experiments conducted in triplicate. Numbers above bars denote p
values (unpaired two-tailed student t -test).
of 4.5 Gy to the whole brain [based on previous work by New-
comb et al. (34)] 8 days after tumor implantation, a second group
received daily i.p. injections of ascorbate (1 g/kg AA) from day 8
to 45 after implantation [based on previous work by Chen et al.
(10)], a third group received both treatments, and a fourth con-
trol group received no treatment at all. Tumor-bearing mice were
culled when weight loss due to tumor growth exceeded 10% of
body weight or neurological symptoms of disease (40), and sur-
vival of animals from all groups are shown in Figure 3. Median
survival for untreated animals survived was 26 days (range 23–
32). Daily doses of intraperitoneal ascorbate did not affect sur-
vival (median 28 days; range 23–30). A single dose of radiation
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FIGURE 3 | Effect of a single dose of radiation, daily i.p. ascorbate and
combined treatment on survival of tumor-bearing C57BL/6 mice.
Tumor-bearing C57BL/6 mice were divided into four groups: one group
received a single dose of 4.5 Gy to the brain 8 days after tumor
implantation, a second group received daily intraperitoneal injections of
ascorbate (day 8–45) after implantation, a third group received both
treatments, and a fourth control group received no treatment. Animals
were sacrificed when they had lost 10% of their weight in 24 h or after
neurological symptoms were evident. Results are representative of four
experiments (two with 1 g/kg ascorbate and two with 2 g/kg ascorbate).
increased survival of tumor-bearing mice significantly (median
43 days; range 31–51; p= 0.002) compared with untreated control
animals. However, in sharp contrast with our in vitro data, tumor-
bearing mice receiving both a single dose of radiation and daily
i.p. ascorbate needed to be culled significantly sooner (median
31 days; range 29–35) than animals treated with a single dose
of radiation alone (p= 0.0275). These data suggest that rather
than making the tumor more sensitive to radiation, ascorbate
protected the tumor from radiation damage. We obtained very
similar results when injecting 2 g/kg i.p. ascorbate daily (results
not shown).
EFFECT OF RADIATION, ASCORBATE, AND COMBINED TREATMENTS ON
TUMOR HISTOLOGY
Tumor-bearing brains were collected from animals at the end-
point of the experiment, which was weight loss of >10% or
neurological symptoms of disease. Tumors were approximately
the same size upon collection but irradiated only mice took longer
to develop these tumors compared with control mice, ascorbate
treated mice, and mice treated with both radiation and ascorbate
(see section above). Analysis of necrosis and presence of blood
in tumors was carried out by H&E staining at multiple sections
across the tumors of at least four mice (a representative exam-
ple is shown in Figure 4). GL261 tumors contained substantial
amounts of intravascular and extravascular blood, regardless of
whether they were treated or not (Figure 5A). Untreated tumors
had variable but low levels of necrosis, making up 0–6% of tumor
area. Radiation treatment doubled the incidence of necrosis, up
to 12% of tumor area. Treatment with ascorbate alone had no
effect on necrosis. Strikingly, addition of ascorbate to radiation
prevented the radiation-induced necrosis, even below the level of
necrosis in control tumors (Figure 5B). These results were con-
sistent with a radio-protective effect of ascorbate on the tumor,
resulting in shorter survival times of tumor-bearing mice receiv-
ing both ascorbate and radiation. Fluorescent confocal microscopy
FIGURE 4 | Representative tumor histology of mice that were not
treated (A), treated with a single dose of 4.5Gy (B), daily i.p ascorbate
(C), and both treatments (D). Analysis of necrosis and presence of blood
in tumors was carried out by H&E staining at multiple sections across the
tumors of several mice. N indicates necrosis. Magnification 4×; bar
represents scale for all four photos (500µM).
FIGURE 5 | Percentage necrosis (A) and statistical analysis (B) of
tumors treated with daily i.p. ascorbate (AA), a single dose of
radiation (Gy), combined treatment (AA+Gy), and no treatment
(C). *p<0.05 is statistically significant.
using anti-PCNA (Proliferating Cell Nuclear Antigen) antibodies
showed a complete lack of proliferation in the normal brain tis-
sues and proliferation in 45–50% of cells throughout the tumors,
regardless of whether the mice had been treated or not (results not
shown).
DISCUSSION
We set out to validate our previous reports on the in vitro radiosen-
sitizing effect of high-dose ascorbate in primary GBM cells (7, 8) in
an intracranial mouse glioma model. Although high-dose ascor-
bate made GL261 cells more sensitive to radiation in vitro, unex-
pectedly it protected tumors derived from GL261 cells implanted
in the brain of mice from radiation injury. To our knowledge,
this is the first time the combination of high-dose ascorbate
with radiation has been tested in mice. Previous studies have
shown that high-dose ascorbate as a single agent (two daily i.p.
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injections of 4 g/kg) significantly retarded tumor growth of rat
9L gliosarcoma cells implanted subcutaneously in the flank of
immunocompromised mice (10). In contrast, our immunocom-
petent mice with brain tumors treated with 1 or 2 g/kg daily i.p.
ascorbate as a single agent developed tumors at the same time
as untreated animals. While it may have been useful to examine
the 4 g/kg doses used in other studies, our tumor-bearing mice
did not cope with the osmotic challenge of buffered ascorbate
sodium salt at doses in excess of 2 g/kg, preventing the escalation
to 4 g/kg.
We hypothesize that the discrepancies between the in vitro data,
the mouse subcutaneous and intracranial data can be explained by
differences in tumor microenvironments. The DNA damage and
other anti-tumor effects of ascorbate require the extracellular con-
version to hydrogen peroxide [reviewed in Ref. (1)]. Laboratory
conditions are characterized by optimal access to oxygen, nutri-
ents, and space in the absence of normal stroma, and extracellular
ascorbate is readily converted to peroxide in this setting. Although
the subcutaneous microenvironment of “flank models” mimics a
“real” tumor with access to oxygen, nutrients, growth factors, and
cytokines available in the systemic blood circulation, it does not
model the conditions in the intracranial interstitial fluid inside the
blood–brain barrier, or the highly specialized interactions between
glioma cells on one hand and astrocytes and microglial cells on
the other hand that may control the fate of ascorbate in the brain
tumor microenvironment.
Astrocytes are a subset of glial cells responsible for maintain-
ing intracranial homeostasis by regulating cerebral blood flow,
neuronal activity through neuron–astrocyte metabolic coupling
and protect neurons from toxic wastes and chemotherapeutic
drugs (41, 42). Small, early stage tumors that develop in this
microenvironment can harness the protective effects of astro-
cytes as shown by Kim and colleagues, who reported that brain
metastases from NCI-H358 lung cancer cells were less sensitive to
rapamycin-induced apoptosis when co-cultured with astrocytes
but not when co-cultured with fibroblasts (41). These authors
also showed that co-culture of human MDA-MB-231 breast cancer
cells with murine astrocytes protected the cancer cells from apop-
tosis by vincristine through upregulation of the anti-apoptotic
survival genes, BCL2L1, TWIST1, and GSTA5. Protection of tumor
cells by astrocytes was mediated by continued physical contact
between astrocytes and tumor cells and direct communication via
GAP junctions (42). Strong expression of these survival genes was
also seen in clinical specimen from breast cancer brain metas-
tases but not in breast cancer metastasized to the lungs (42).
With respect to radiation sensitivity, human NSC11 stem cell-
like GBM cells grown in vitro were reported to be much more
sensitive to radiation than the same cells implanted in mouse
brains (43, 44).
The brain microenvironment is also unique with respect to
ascorbate metabolism. Ascorbate passes through the blood–brain
barrier very slowly but it is actively transported into the cere-
brospinal fluid via the high affinity sodium-dependent vitamin
C transporter, SVCT2. Ependymal cells that line the choroid
plexi and produce cerebrospinal fluid from blood plasma highly
express SVCT2 (3, 45–47). Neurons further concentrate intracel-
lular ascorbate to millimolar levels (3, 45, 47), where it acts as a free
radicals scavenger (3), assists the cellular hypoxia response through
hydroxylation of hypoxia-inducible factor 1α (48), promotes col-
lagen synthesis, and neuronal maturation and transmission (3).
Therefore, ascorbate concentrations in the brain are very high
(2–10 mM) compared with liver (0.8–1 mM), muscle (400µM),
cerebrospinal fluid and interstitial fluid (160–400µM), and blood
plasma (40–60µM) (3). These high ascorbate concentrations in
the brain are generated through active transport via the high
affinity sodium-dependent vitamin C transporter, SVCT2, which
is highly expressed on ependymal cells and neurons (3, 45). So,
rather than through the blood–brain barrier, ascorbate is actively
transported into the cerebrospinal fluid through SVCT2.
Astrocytes and microglial cells (central nervous system resi-
dent macrophages) do not normally express SVCT2 but acquire
ascorbate in its oxidized form, dehydroascorbate (DHA), imported
via the glucose transporter, GLUT1. Once inside the cell DHA is
rapidly reduced to ascorbate, resulting in intracellular ascorbate
levels in astrocytes and microglial cells similar to those of cere-
brospinal and interstitial fluid of 160–400µM, adding to their
anti-oxidant capacity (3, 45).
The mechanism of ascorbate uptake in gliomas and GBM is
likely to include both SVCT2 and GLUT1. A recent report suggests
that proliferative neural progenitor cells up-regulate SVCT2 in
response to ascorbate (49), a mechanism that could also transport
ascorbate into GBMs. An extensive analysis of gene expression and
DNA copy number in gliomas (50–52) has indicated the SVCT2
locus is amplified in gliomas, and expression is significantly higher
than in normal brain tissue. However, data from other expres-
sion studies suggest that SVCT2 expression in gliomas may be lost
(53, 54). Further, gene expression does not guarantee transporter
activity. Rodriguez and colleagues showed that the high SVCT2
expression in the TC620 oligodendroglioma cell line was offset by
its lack of activity and intracellular location (55). In vivo, the acidic
tumor environment is likely to reduce the activity of the SVCT2
transporters, which have an optimal activity at a slightly alkaline
pH (56). For gliomas that lack an active SVCT2, tumor associated
microglial cells, which can make up to 30% of tumor mass in high
grade gliomas could supply the glioma cells with DHA taken up
via GLUT1 (57).
Regardless of the mechanism of uptake, glioma cells may be
able to rapidly acquire significant quantities of ascorbate. This
will have two effects – first, it will prevent the extracellular con-
version of ascorbate to hydrogen peroxide, neutralizing the DNA
damage potential. Second, the anti-oxidant activity of ascorbate
will protect the cell from radiation-induced oxidative damage.
Taken together, our results strongly suggest that the unique brain
microenvironment promotes accumulation of ascorbate inside
GBM cells to concentrations high enough to facilitate radioprotec-
tion. This is in sharp contrast with the reported pro-oxidant effect
of extracellular ascorbate in vitro and in flank xenograft models
[reviewed in Ref. (1)].
Although our orthotopic glioma model mimics the brain
microenvironment and is therefore clinically more relevant than
subcutaneous flank models, it has certain limitations that make
extrapolation to the clinical setting problematic. GL261 cells
represent a stage II–III glioma and not a stage IV GBM, form
well-defined tumors rather than the diffuse pattern often seen in
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GBMs and are a lot more sensitive to radiation and ascorbate
than true primary and established GBM cell lines as shown pre-
viously (7). Perhaps more importantly, our mice received only a
single dose of 4.5 Gy, whereas standard radiation therapy for GBM
patients consists of daily fractions of 2 Gy over 10 weeks to a total
dose of 60 Gy (24, 58). In addition, most GBM patients will receive
the chemotherapy drug temozolomide at the same time as radia-
tion therapy as well as in the adjuvant setting in the form of several
cycles after completion of radiation therapy (24). We also did not
measure tissue ascorbate levels in this study, which should be done
in future studies to determine to what extent the injected ascorbate
affects ascorbate levels in both brain and tumor tissue. However,
although our findings cannot be directly extrapolated to the clini-
cal setting, the underlying problem with combining radiation and
high-dose ascorbate remains the same: does the ascorbate get into
the glioma cells and act as an anti-oxidant, protecting the tumor
from radiation OR does it remain outside the cells, generating
hydrogen peroxide and acting as a pro-oxidant. It may be useful in
this context to test individual patient tumors for the presence and
activity of SVCT2.
In contrast to combining high-dose ascorbate with radiation
in brain cancers, clinical studies combining high-dose ascorbate
with chemotherapeutic agents for metastatic ovarian and pan-
creatic cancer have produced more promising results. Adding
high-dose ascorbate to existing chemotherapy regimens decreased
chemotherapy-related toxicities and increased patient overall sur-
vival even if the latter was not statistically significant in these small
phase I trials (11, 22, 23). It is important to note, however, that
these clinical studies were not done in patients with brain can-
cers, and included drugs that do not work primarily by generating
free radicals. Ascorbate would not have affected the efficacy of
these chemotherapy drugs whether it acted as a pro-oxidant or an
anti-oxidant.
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